About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Innovation Engine New Era Microbiome Therapeutics Discuva Platform Scientific Literature & Publications Investors & Media Investor Center Media Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Summit Presentations Careers
Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study July 12, 2021 By Dave Gancarz
Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study
Metagenomic Analysis of the Differential Impact of Ridinilazole and Vancomycin on the Gut Microbiota in a Phase II Study July 12, 2021 By Dave Gancarz